Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1992 1
1993 1
1994 2
1995 2
1997 1
1998 2
1999 1
2000 4
2001 2
2002 2
2003 3
2004 3
2005 4
2006 6
2007 6
2008 5
2009 4
2010 2
2011 7
2012 7
2013 6
2014 6
2015 12
2016 7
2017 7
2018 8
2019 8
2020 8
2021 5
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 28373455

111 results

Results by year

Filters applied: . Clear all
Page 1
[Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany].
Lehmann J, Retz M, Steiner G, Albers P, Jaeger E, Knuth A, Lippert C, Koser M, Stockamp K, Otto C, Melchior H, Fassmann C, Potratz C, Loch T, Derigs HG, Becker T, Kälble T, Piechota HJ, Hertle L, Weinknecht S, Weissbach L, Al-Mwalad M, Hamza A, Henss H, Brkovic D, Pomer S, Roloff J, Walz P, Muschter R, Tunn U, Winter E, Bub P, Kaldenbach U, Roth S, Brauers A, Jakse G, Richter AE, Wirth M, Hartlapp J, Van Ahlen H, Stöckle M. Lehmann J, et al. Urologe A. 2003 Aug;42(8):1074-86. doi: 10.1007/s00120-003-0317-4. Epub 2003 Apr 2. Urologe A. 2003. PMID: 14513232 Clinical Trial. German.
Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group.
Kuroda M, Kotake T, Akaza H, Hinotsu S, Kakizoe T. Kuroda M, et al. Jpn J Clin Oncol. 1998 Aug;28(8):497-501. doi: 10.1093/jjco/28.8.497. Jpn J Clin Oncol. 1998. PMID: 9769784 Clinical Trial.
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, Boehle A, Chevreau C, Paz-Ares L, Laufman LR, Winquist E, Raghavan D, Marreaud S, Collette S, Sylvester R, de Wit R. Bellmunt J, et al. J Clin Oncol. 2012 Apr 1;30(10):1107-13. doi: 10.1200/JCO.2011.38.6979. Epub 2012 Feb 27. J Clin Oncol. 2012. PMID: 22370319 Free PMC article. Clinical Trial.
Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study.
Nakagawa T, Komemushi Y, Kawai T, Otsuka M, Miyakawa J, Uemura Y, Kanatani A, Taguchi S, Naito A, Suzuki M, Nishimatsu H, Hirano Y, Tanaka Y, Matsumoto A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Nakagawa T, et al. World J Urol. 2017 Oct;35(10):1569-1575. doi: 10.1007/s00345-017-2032-6. Epub 2017 Apr 10. World J Urol. 2017. PMID: 28397000
111 results